Published in Circulation on October 25, 2005
Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol (2013) 2.30
Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol (2012) 2.24
NOS1AP is a genetic modifier of the long-QT syndrome. Circulation (2009) 2.00
Congenital long QT syndrome. Orphanet J Rare Dis (2008) 1.58
Vagal reflexes following an exercise stress test: a simple clinical tool for gene-specific risk stratification in the long QT syndrome. J Am Coll Cardiol (2012) 1.58
Autonomic control of heart rate and QT interval variability influences arrhythmic risk in long QT syndrome type 1. J Am Coll Cardiol (2015) 1.52
Importance of Knowing the Genotype and the Specific Mutation When Managing Patients with Long QT Syndrome. Circ Arrhythm Electrophysiol (2008) 1.48
Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res (2012) 1.25
Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J (2014) 1.11
Identification of a KCNQ1 polymorphism acting as a protective modifier against arrhythmic risk in long-QT syndrome. Circ Cardiovasc Genet (2013) 1.03
Long QT syndrome: beyond the causal mutation. J Physiol (2013) 1.00
Of founder populations, long QT syndrome, and destiny. Heart Rhythm (2009) 0.95
Long QT syndrome in South Africa: the results of comprehensive genetic screening. Cardiovasc J Afr (2013) 0.94
QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. J Addict Dis (2011) 0.94
Systems biology and cardiac arrhythmias. Lancet (2012) 0.92
Voltage-Dependent Gating: Novel Insights from KCNQ1 Channels. Biophys J (2016) 0.87
Prevalence of Significant Genetic Variants in Congenital Long QT Syndrome is Largely Underestimated. Front Pharmacol (2012) 0.86
Mendelian-inherited heart disease: a gateway to understanding mechanisms in heart disease Update on work done at the University of Stellenbosch. Cardiovasc J Afr (2009) 0.86
Evolutionary analyses of KCNQ1 and HERG voltage-gated potassium channel sequences reveal location-specific susceptibility and augmented chemical severities of arrhythmogenic mutations. BMC Evol Biol (2008) 0.85
Molecular Pathophysiology of Congenital Long QT Syndrome. Physiol Rev (2017) 0.85
AKAP9 is a genetic modifier of congenital long-QT syndrome type 1. Circ Cardiovasc Genet (2014) 0.83
Phenotype, origin and estimated prevalence of a common long QT syndrome mutation: a clinical, genealogical and molecular genetics study including Swedish R518X/KCNQ1 families. BMC Cardiovasc Disord (2014) 0.83
Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances. Biology (Basel) (2017) 0.81
Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome. Neth Heart J (2010) 0.80
Race and gender representation of hypertrophic cardiomyopathy or long QT syndrome cases in a South African research setting. Cardiovasc J Afr (2007) 0.79
Molecular mechanisms of inherited arrhythmias. Curr Genomics (2008) 0.78
Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndrome. Heart Rhythm (2011) 0.78
Partial restoration of the long QT syndrome associated KCNQ1 A341V mutant by the KCNE1 β-subunit. Biochim Biophys Acta (2011) 0.77
Phenotypic variability in Caucasian and Japanese patients with matched LQT1 mutations. Ann Noninvasive Electrocardiol (2008) 0.77
Enhanced effects of isoflurane on the long QT syndrome 1-associated A341V mutant. Anesthesiology (2015) 0.77
Phenotype guided characterization and molecular analysis of Indian patients with long QT syndromes. Indian Pacing Electrophysiol J (2016) 0.76
A dual mechanism for I(Ks) current reduction by the pathogenic mutation KCNQ1-S277L. Pacing Clin Electrophysiol (2011) 0.76
Multiscale complexity analysis of the cardiac control identifies asymptomatic and symptomatic patients in long QT syndrome type 1. PLoS One (2014) 0.76
Risk stratification in young patients with channelopathies. Indian Pacing Electrophysiol J (2010) 0.75
Molecular pathogenesis of long QT syndrome type 1. J Arrhythm (2016) 0.75
Sudden death by stress: how far under the nerves should we dig to find out why LQT1 patients die? J Am Coll Cardiol (2013) 0.75
Filamin C: a novel component of the KCNE2 interactome during hypoxia. Cardiovasc J Afr (2016) 0.75
Genetic modulation of impaired cardiac conduction: sodium channel beta4 subunit missing in action. Circ Res (2009) 0.75
Murine Electrophysiological Models of Cardiac Arrhythmogenesis. Physiol Rev (2017) 0.75
[Standard-ECG]. Herzschrittmacherther Elektrophysiol (2008) 0.75
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20
Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell (2004) 7.45
Risk stratification in the long-QT syndrome. N Engl J Med (2003) 7.25
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics (2010) 7.07
Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet (2010) 6.44
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol (2013) 4.85
Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med (2005) 4.85
The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med (2013) 4.37
Prevalence of the congenital long-QT syndrome. Circulation (2009) 4.32
Concern Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation (2002) 4.16
Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation (2007) 4.10
PiggyBac transposon-mediated gene transfer in human cells. Mol Ther (2007) 4.07
Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest (2006) 4.06
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet (2011) 3.94
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85
Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci (2010) 3.84
Molecular basis of an inherited epilepsy. Neuron (2002) 3.77
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA (2005) 3.51
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med (2009) 3.35
Identification of genomic predictors of atrioventricular conduction: using electronic medical records as a tool for genome science. Circulation (2010) 3.35
Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA (2004) 3.24
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest (2003) 3.00
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation (2008) 2.83
Two cases of sudden unexpected death in epilepsy in a GEFS+ family with an SCN1A mutation. Epilepsia (2008) 2.81
KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation (2005) 2.78
Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation (2008) 2.72
Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation (2006) 2.72
Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation (2013) 2.66
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm (2007) 2.62
Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res (2012) 2.61
The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation (2006) 2.58
Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation (2008) 2.56
Drug-induced long QT syndrome. Pharmacol Rev (2010) 2.55
Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest (2008) 2.54
Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I. J Clin Invest (2009) 2.54
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation (2007) 2.38
Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J (2009) 2.37
Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med (2008) 2.34
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Unmasking of brugada syndrome by lithium. Circulation (2005) 2.30
Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol (2013) 2.30
Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation (2007) 2.28
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation (2003) 2.28
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm (2011) 2.26
Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol (2012) 2.24
Structure of KCNE1 and implications for how it modulates the KCNQ1 potassium channel. Biochemistry (2008) 2.22
Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol (2003) 2.22
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation (2002) 2.20
Cost-effectiveness of neonatal ECG screening for the long QT syndrome. Eur Heart J (2006) 2.15
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol (2011) 2.15
Identification of novel interactions between domains of Myosin binding protein-C that are modulated by hypertrophic cardiomyopathy missense mutations. Circ Res (2002) 2.13
Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet Med (2010) 2.09
Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation (2013) 2.06
Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J (2009) 2.06
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol (2007) 2.04
Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol (2008) 2.04